17 research outputs found
Π‘Π»ΡΡΠ°ΠΉ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ IgG4-ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ Ρ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠ°
IgG4-related disease (IgG4-RD) is a rare immune-mediated fibroinflammatory disease that is characterized by the occurrence of nodules in one or more organs and proceeds in most patients with the elevated levels of IgG4 in serum and/or in the tissues of the affected organs. The majority of patients are elderly men, and the disease in most cases has a slowly progressing systemic course. The cases of isolated IgG4-related injury to the viscera, which are much less common than the systemic type of the disease, are a very difficult differential diagnosis, and biopsy of these organs is associated with technical difficulties and poses a threat to the patient's health. The paper describes just such a case. It is interesting from several points of view: firstly, a rare site (solitary pulmonary nodular lesion); secondly, clinical and laboratory features (childhood onset, no immunological abnormalities β both higher serum IgG4 levels and lower complement components).Clinicians should remember that IgG4-RD does not always have a systemic course and characteristic serological markers. In these cases, histological verification of the diagnosis is of particular importance. If the histological pattern of a fibroinflammatory pseudotumor is identified, especially in the presence of multiple nodules, IgG4-RD should always be included in the differential diagnosis.Β IgG4-ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ (IgG4-Π‘Π) β ΡΠ΅Π΄ΠΊΠΎΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΡΠΈΠ±ΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠ΅Π΅ΡΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠ΅ΠΌ ΡΠ·Π»ΠΎΠ²ΡΡ
ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΠΎΠ΄Π½ΠΎΠΌ ΠΈΠ»ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½Π°Ρ
ΠΈ ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠ΅Π΅ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π½Ρ IgG4 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΈ/ΠΈΠ»ΠΈ Π² ΡΠΊΠ°Π½ΡΡ
ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ². ΠΡΠ½ΠΎΠ²Π½Π°Ρ ΡΠ°ΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² β ΠΏΠΎΠΆΠΈΠ»ΡΠ΅ ΠΌΡΠΆΡΠΈΠ½Ρ, Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ»ΡΡΠ°Π΅Π² ΠΈΠΌΠ΅Π΅Ρ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠ΅Π΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅. ΠΡΠ΅Π½Ρ ΡΠ»ΠΎΠΆΠ½Ρ Π΄Π»Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠ»ΡΡΠ°ΠΈ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ IgG4-ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ Π³ΠΎΡΠ°Π·Π΄ΠΎ ΡΠ΅ΠΆΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π±ΠΈΠΎΠΏΡΠΈΠΈ Π΄Π°Π½Π½ΡΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΡΠΎΠΏΡΡΠΆΠ΅Π½ΠΎ Ρ ΡΠ΅Ρ
Π½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΡΡΠ΄Π½ΠΎΡΡΡΠΌΠΈ ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠ³ΡΠΎΠ·Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΠΈΠΌΠ΅Π½Π½ΠΎ ΡΠ°ΠΊΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ. ΠΠ½ ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠ΅Π½ Ρ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΡΠΎΡΠ΅ΠΊ Π·ΡΠ΅Π½ΠΈΡ: Π²ΠΎ-ΠΏΠ΅ΡΠ²ΡΡ
, ΡΠ΅Π΄ΠΊΠΎΠΉ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ β ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΡΠ·Π»ΠΎΠ²ΠΎΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ Π»Π΅Π³ΠΊΠΈΡ
; Π²ΠΎ-Π²ΡΠΎΡΡΡ
, ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌΠΈ (Π΄Π΅Π±ΡΡ Π² Π΄Π΅ΡΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅, ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΊΠ°ΠΊΠΈΡ
-Π»ΠΈΠ±ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΠΉ β ΠΊΠ°ΠΊ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ IgG4 ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ, ΡΠ°ΠΊ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ°).ΠΠ»ΠΈΠ½ΠΈΡΠΈΡΡΠ°ΠΌ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΏΠΎΠΌΠ½ΠΈΡΡ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ IgG4-Π‘Π Π½Π΅ Π²ΡΠ΅Π³Π΄Π° ΠΈΠΌΠ΅Π΅Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠ΅ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ. Π ΡΡΠΈΡ
ΡΠ»ΡΡΠ°ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π²Π΅ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° ΠΈΠΌΠ΅Π΅Ρ ΠΎΡΠΎΠ±ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Ρ ΡΠΈΠ±ΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Β«ΠΏΡΠ΅Π²Π΄ΠΎΠΎΠΏΡΡ
ΠΎΠ»ΠΈΒ», ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ ΠΏΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ·Π»ΠΎΠ²ΡΡ
ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ, Π² Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ Π²ΡΠ΅Π³Π΄Π° ΡΠ»Π΅Π΄ΡΠ΅Ρ Π²ΠΊΠ»ΡΡΠ°ΡΡ IgG4-Π‘Π.
Π’ΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π²Π°ΡΠΈΠ°Π½Ρ Π΄ΠΈΡΡΡΠ·Π½ΠΎΠΉ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΡΡΠΏΠ½ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠΎΠΌΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π¨Π΅Π³ΡΠ΅Π½Π° ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΡΠ»ΡΡΠ°Ρ ΠΈ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ)
This article describes a case of a transformed diffuse large B-cell lymphoma of the stomach in a patient with Sjogrenβs disease (SjD) and systemic sclerosis (SSc), as well as a brief review of the literature on lymphoproliferative diseases in SjD and SSc.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΡΠ»ΡΡΠ°Ρ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π΄ΠΈΡΡΡΠ·Π½ΠΎΠΉ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΡΡΠΏΠ½ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π»ΠΈΠΌΡΠΎΠΌΡ ΠΆΠ΅Π»ΡΠ΄ΠΊΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Ρ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π¨Π΅Π³ΡΠ΅Π½Π° (ΠΠ¨) ΠΈ Π»ΠΈΠΌΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ (Π‘Π‘Π), Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊΡΠ°ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ Π»ΠΈΠΌΡΠΎΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌ ΠΏΡΠΈ ΠΠ¨ ΠΈ Π‘Π‘Π. ΠΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ ΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΊΠ°Π·Π°Π½Π½ΡΠΌΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡΠΌΠΈ
Diagnosis of IgG4 - related ophthalmic disease in a group of patients with various lesions of the eye and orbits
Purpose of the study. To provide demographic, clinical, laboratory, ultrasound, radiological, morphological/ immunomorphological phenotype of IgG4-related ophthalmic diseases, which allowsmaking a differential diagnosis with granulomatous, autoimmune, inflammatory, endocrine and hematologic diseases affecting the eye and orbits. Materials and methods. From 2004 to 2016 108 (78.2%) of the 138 patients were diagnosed with non-tumoral lesions of eye and orbits. In 48 patients (35%) at admission and 5 patients in the follow were diagnosed IgG4-related ophthalmic disease. In the analysis of 82 (f-44, m-38) patients with IgG4-related disease, localization of lesions in orbit observed in 53 (f-36, m-17) and it was the most frequent involvement in patients with IgG4-related disease (64.5%). Only 7 patients had isolated IgG4-related ophthalmic disease, whereas 46 patients (87%) had involvement of 2-7 locations, as a manifestation of IgG4-related systemic disease.During the examination, the average age of patients with IgG4-related ophthalmic disease was 47.5 years (19-73 years). Median time to diagnosis was 52.8 months before 2004 and 36 months 2004-2016. Results. We noted the predominance of females in the ratio 2: 1 inthe group of patients with IgG4-related ophthalmic disease. Edema of the eyelids, nasal congestion (55-60%), tumor-like formations of the upper eyelids and increased lacrimation prevailed at the onset of the disease, whereas such functional impairment like limited mobility and pain in eyeballs, exophthalmos, ptosis and diplopia appeared later at 15-38% with a loss visual acuity in one case. Bilateral lesion (86%), mainly affecting the lacrimal glands (93.5%), infiltration of the extraocular muscles (83.5%) and retrobulbar tissue with a thickening of the optic nerve in one third of patients were the main localizations IgG4-related ophthalmic disease. Clinical symptoms were accompanied by the appearance of moderate inflammatory activity (38%), increased levels IgG (44%), IgG4(88%) and IgE (61%). Indicators of autoimmune disorders observed in 6-22% of patients, most often in patients with simultaneous involvement of the salivary glands. Significant lymphoplasmacytic infiltration (94%) with a ratio of plasma cells (IgG4/IgG) secreting IgG4> 40% (90%) with fibrosis formation (94%) and follicle formation (71%) with a moderate amount of eosinophils (34%) were the major morphological / immunomorphological manifestations of IgG4-related ophthalmic disease. Signs of vasculitis and obliterative phlebitis were found in a small amount of patients. Conclusion. Determination of elevated levels of IgG-4 / IgE in patients with edema, pseudotumor of the eyelid, sinusitis and increase of the palpebral lobe of the lacrimal gland suggests the presence of IgG4-related ophthalmic disease. Minimally invasive incisional biopsy of lacrimal glands and salivary glands followed by morphological / immunomorphological research is needed for the correct diagnosis. Diagnostic orbitotomy in ophthalmic hospitals in such cases is inexpedient, since it leads to the development of dry eye. Massive lymphoplasmacytic infiltration with IgG4 / IgG ratio more than 40%, advanced fibrosis in biopsiesof the orbits tissue or salivary glands when combined lesions are required for the making the diagnosis of IgG4-related ophthalmic disease
IgG4-RELATED DISEASE. CLINICAL NOTES
IgG4-related diseases are a new nosological entity that encompasses a few previously known diseases. IgG4-relatedΒ systemic disease is diagnosed if two or more affected organs are detected. This group of diseases has two similar signs:Β serological (elevated serum IgG4 subclass concentrations) and histological (organ and tissue infiltration from plasmo-cytes secreting IgG4, and eosinophils, and the development of fibrosclerosis and phlebitis obliterans).Β The paper describes two cases. In one case, a multisystemic disease was observed virtually at its onset whereas in theΒ other this lesion was diagnosed several years after the natural course of the disease
ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ PD-L1-ΡΡΠ°ΡΡΡΠ° ΠΎΠΏΡΡ ΠΎΠ»ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Background.New potential biomarker for patients with metastatic hormone-naive prostate cancer (PCa) might be detection of programmed death ligand 1 (PD-L1) expression in tumor which is associated with worsened results of treatment and decreased survival in patients with pancreatic cancer, lung cancer and other malignant tumors.Objective: to evaluate the prognostic value of positive tumor PD-L1 status on time to castration resistance (CRPCa) in patients with metaΒstatic PCa receiving hormonal androgen deprivation therapy in first-line systemic treatment.Materials and methods.A total of 35patients with metastatic hormone-naive PCa receiving androgen deprivation therapy with luteinizing hormone-releasing hormone analogue and follow-up at N.N. Blokhin National Medical Research Center of Oncology were recruited in our prospective study. Tumor features of all patients were evaluated for PD-L1 expression on tumor cells by immunohistochemical studies of paraffin block sections obtained under the visual control of the pathologist using a set of monoclonal anti-PD-L1 antibody (28-8) (ab 205921) and Ventana BenchMark GXSlide staining system. Tumor tissue was obtained before starting androgen deprivation therapy. The expression level of PD-L1 >1 % in tumor cells was taken for the positive tumor PD-L1(+) status.Results. Median follow-up was 32.8 months. Positive tumor PD-L1(+) status was identified in 10 (28.6 %) cases. Median time to CRPCa was significantly lower in patients with PD-L1(+) status, than in negative PD-L1(β) status (21.44 vs. 49.12, p = 0.006 log rank test). MultiΒvariate Cox regression analysis confirmed independence prognostic value of PD-L1(+) associated with decreased time to CRPCa (hazard ration 5.95, 95 % confidence interval 1.97β17.99; p = 0.002), including in subgroup of patients with low-volume metastatic disease (hazard ration 7.33, 95 % confidence interval 1.81β29.60; p = 0.005).Discussion. Interaction of PD-1 receptors and its ligands PD-L1/PD-L2 is the key mechanism causing tumor immune escape and progression of the cancer. There are discussed certain ways of inducing PD-L1 expression and its prognostic value on aggressive nonmetastatic PCa. High frequency of positive PD-L1 status was revealed in rare histological subtypes of PCa associated with unfavorable prognosis and visceral metastasis.Conclusion.The results of our study demonstrated the positive tumor PD-L1 status as an independent unfavorable prognostic factorfor patients with metastatic hormone-naive PCa associated with decreased time to castration resistance, including in patients with low volume metastatic disease.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ
Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³ΠΎΡΠΌΠΎΠ½ΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ (Π ΠΠ) ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π»ΠΈΠ³Π°Π½Π΄Π° Π±Π΅Π»ΠΊΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠΈΡΡΠ΅ΠΌΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π³ΠΈΠ±Π΅Π»ΠΈ (PD-L1) Π² ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, Π°ΡΡΠΎΒΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Ρ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° PD-L1(+) ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π° Π²ΡΠ΅ΠΌΡ Π΄ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΊΠ°ΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ (ΠΠ Π ΠΠ) Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π ΠΠ, ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΡ
Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΡΡ Π°Π½Π΄ΡΠΎΠ³Π΅Π½Π΄Π΅ΠΏΡΠΈΠ²Π°ΡΠΈΠΎΠ½Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π² 1-ΠΉ Π»ΠΈΠ½ΠΈΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ 35ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³ΠΎΡΠΌΠΎΠ½ΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π ΠΠ, ΠΊΠΎΡΠΎΡΡΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ Π°Π½Π΄ΡΠΎΠ³Π΅Π½Π΄Π΅ΠΏΡΠΈΠ²Π°ΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°Π½Π°Π»ΠΎΠ³Π°ΠΌΠΈ Π»ΡΡΠ΅ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅Π³ΠΎ Π³ΠΎΡΠΌΠΎΠ½Π° ΡΠΈΠ»ΠΈΠ·ΠΈΠ½Π³-Π³ΠΎΡΠΌΠΎΠ½Π° ΠΈ ΠΊΠΎΡΠΎΡΡΠ΅ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΠΈΡΡ ΠΏΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π² ΠΠΠΠ¦ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π.Π. ΠΠ»ΠΎΡ
ΠΈΠ½Π°. ΠΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Π±ΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ΅Π·ΠΎΠ² ΠΏΠ°ΡΠ°ΡΠΈΠ½ΠΎΠ²ΡΡ
Π±Π»ΠΎΠΊΠΎΠ², ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΏΠΎΠ΄ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³Π° Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΡΠ΅Π»Π° Anti-PD-L1 antibody (28-8) (ab 205921) Π½Π° ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠ΅ΠΉΠ½Π΅ΡΠ΅ Ventana BenchMark GX. ΠΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΉ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π» Π±ΡΠ» ΠΏΠΎΠ»ΡΡΠ΅Π½ Π΄ΠΎ Π½Π°ΡΠ°Π»Π° Π°Π½Π΄ΡΠΎΠ³Π΅Π½Π΄Π΅ΠΏΡΠΈΠ²Π°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ° ΡΡΠ°ΡΡΡ PD-L1(+) ΠΏΡΠΈΠ½ΠΈΠΌΠ°Π»ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 >1 % Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ΅Π΄ΠΈΠ°Π½Π° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 32,8 ΠΌΠ΅Ρ. Π‘ΡΠ°ΡΡΡ PD-L1(+) ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ Π² 10 (28,6 %) ΡΠ»ΡΡΠ°ΡΡ
. ΠΠ΅Π΄ΠΈΠ°Π½Π° Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π΄ΠΎ ΠΠ Π ΠΠ Π±ΡΠ»Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅ Π² Π³ΡΡΠΏΠΏΠ΅ PD-L1(+), ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ PD-L1(β) (21,44 ΠΌΠ΅Ρ ΠΏΡΠΎΡΠΈΠ² 49,12 ΠΌΠ΅Ρ; Ρ = 0,006). ΠΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΠΎΠΊΡΠ° ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ» PD-L1(+) ΠΊΠ°ΠΊ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΉ ΡΠ°ΠΊΡΠΎΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π΄ΠΎ ΠΠ Π ΠΠ (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² 5,95, 95 % Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» 1,97β17,99; Ρ = 0,002), Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π² ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² 7,33, 95 % Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» 1,81β29,60; Ρ = 0,005).ΠΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° PD-1 Ρ Π΅Π³ΠΎ Π»ΠΈΠ³Π°Π½Π΄Π°ΠΌΠΈ PD-L1/PD-L2 ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΊΠ»ΡΡΠ΅Π²ΡΠΌ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠΌ Π² Β«ΡΡΠΊΠΎΠ»ΡΠ·Π°Π½ΠΈΠΈΒ» ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΎΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π½Π°Π΄Π·ΠΎΡΠ°. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1, Π° ΡΠ°ΠΊΠΆΠ΅ Π΅Π΅ ΡΠ²ΡΠ·Ρ Ρ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΡΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ ΠΏΡΠΈ Π½Π΅ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΌ Π ΠΠ. ΠΡΡΠΎΠΊΠ°Ρ ΡΠ°ΡΡΠΎΡΠ° ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° PD-L1 ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΏΡΠΈ ΡΠ΅Π΄ΠΊΠΈΡ
Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΠΌΠ°Ρ
Π ΠΠ ΠΈ Π²ΠΈΡΡΠ΅ΡΠ°Π»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°Ρ
.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΡΠ°ΡΡΡ PD-L1 ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³ΠΎΡΠΌΠΎΠ½ΠΎΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π ΠΠ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π΄ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ Π ΠΠ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΏΡΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ
ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠ°ΡΡΡΠ° ΠΌΠΈΠΊΡΠΎΡΠ°ΡΠ΅Π»Π»ΠΈΡΠ½ΠΎΠΉ Π½Π΅ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π·Π°Π±ΡΡΡΠΈΠ½Π½ΡΠΌΠΈ Π½Π΅ΠΎΡΠ³Π°Π½Π½ΡΠΌΠΈ Π»Π΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ°ΠΌΠΈ
Background. Leiomyosarcoma is one of the most common types of soft tissue sarcomas. Radical surgical resection with subsequent adjuvant chemotherapy remain the most effective treatment approach. Immunotherapy based on inhibition of PD-L1 (programmed death ligand 1) or its receptor PD1 (programmed death 1) is considered a promising treatment option. Level of PD-L1 expression in tumor cells and presence of microsatellite instability (ΠSI) could be considered prognostic and predictive markers of disease progression and effectiveness of immunotherapy.The study objective is to determine PD-L1 expression level and ΠSI status in patients with retroperitoneal leiomyosarcomas and evaluate their effect on overall and recurrence-free survival.Materials and methods. The study included 57 patients with retroperitoneal leiomyosarcomas who underwent surgical or combination treatment. Analysis of clinical and morphological characteristics was performed; results of surgical treatment were researched. Evaluation of PD-L1 expression and MSI status was performed using immunohistochemical and molecular genetic analysis.Results. PD-L1 expression and MSI status were evaluated in 41 patients of 57. In 10 (24 %) of 41 cases, positive PD-L1 expression was observed (expression level 3β50 %). In 1 (2.4 %) patient, the primary tumor and metastatic lesion had low MSI level (MSI-low, MSI-L). Median follow-up was 31 months. In patients with positive PD-L1 expression, higher Ki-67 proliferative index was observed compared to patients with PD-L1 negative tumors (58.8 and 47.8 % respectively; Ρ = 0.02), as well as significantly lower median overall survival for grade II tumors (30 and 105 months; p = 0.043). In grade III leiomyosarcomas, a trend towards lower median overall survival in patients with PD-L1βnegative tumors (31.0 months) compared to patients with PD-L1 expression (61.2 months) (Ρ = 0.11) was observed.Conclusion. Among patients with retroperitoneal leiomyosarcomas, positive expression of PD-L1 was observed in 24 % (10 / 41) of cases and MSI-low status was found in 2.4 % (1 / 41) of cases. In patients with grade 2 tumors, positive PD-L1 expression is associated with significantly lower overall survival. PD-L1 expression in patients with retroperitoneal leiomyosarcomas could be considered a prognostic marker and a potential therapeutic target.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· ΡΠ°ΠΌΡΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΌΡΠ³ΠΊΠΈΡ
ΡΠΊΠ°Π½Π΅ΠΉ. Π Π°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΎΡΡΠ°Π΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ. ΠΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ β ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π½Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π°Π½ΡΠΈΡΠ΅Π», Π±Π»ΠΎΠΊΠΈΡΡΡΡΠΈΡ
Π»ΠΈΠ³Π°Π½Π΄ PD-L1 (programmed death ligand 1) ΠΈΠ»ΠΈ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡ PD-1 (programmed death 1). Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΌΠΈΠΊΡΠΎΡΠ°ΡΠ΅Π»Π»ΠΈΡΠ½ΠΎΠΉ Π½Π΅ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΠΈ (ΠSI) ΠΌΠΎΠ³ΡΡ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΊΠ°ΠΊ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½ΡΠΉ ΠΌΠ°ΡΠΊΠ΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΠΈ ΡΡΠ°ΡΡΡ ΠSI Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π·Π°Π±ΡΡΡΠΈΠ½Π½ΡΠΌΠΈ Π½Π΅ΠΎΡΠ³Π°Π½Π½ΡΠΌΠΈ Π»Π΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ°ΠΌΠΈ ΠΈ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΎΠ±ΡΡΡ ΠΈ Π±Π΅Π·ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π½ΡΡ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 57 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π·Π°Π±ΡΡΡΠΈΠ½Π½ΡΠΌΠΈ Π½Π΅ΠΎΡΠ³Π°Π½Π½ΡΠΌΠΈ Π»Π΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ°ΠΌΠΈ, ΠΊΠΎΡΠΎΡΡΠΌ Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΠΎΡΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΠ»ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΈΠ·ΡΡΠ΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΠΈ ΠSI ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ 41 ΠΈΠ· 57 ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π±ΡΠ»Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1. Π 10 (24 %) ΠΈΠ· 41 ΡΠ»ΡΡΠ°Ρ Π²ΡΡΠ²Π»Π΅Π½Π° ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ (ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ» 3β50 %). Π£ 1 (2,4 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΏΠ΅ΡΠ²ΠΈΡΠ½Π°Ρ ΠΎΠΏΡΡ
ΠΎΠ»Ρ ΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΡΠ°Π³ ΠΈΠΌΠ΅Π»ΠΈ Π½ΠΈΠ·ΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΠSI (MSI-low, MSI-L). ΠΠ΅Π΄ΠΈΠ°Π½Π° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π·Π° Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 31 ΠΌΠ΅Ρ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ PD-L1 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Ρ PD-L1βΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ Π²ΡΡΠ²Π»Π΅Π½ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ki-67 (58,8 ΠΈ 47,8 % ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; Ρ = 0,02), Π° ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠ·ΠΊΠ°Ρ ΠΌΠ΅Π΄ΠΈΠ°Π½Π° ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΏΡΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
II ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΠΈ (30 ΠΈ 105 ΠΌΠ΅Ρ; p = 0,043). ΠΡΠΈ Π»Π΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ°Ρ
III ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ ΡΡΠ΅Π½Π΄ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΌΠ΅Π΄ΠΈΠ°Π½Ρ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ PD-L1βΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΠΌΠΈ (31,0 ΠΌΠ΅Ρ) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 (61,2 ΠΌΠ΅Ρ) (Ρ = 0,11).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π§Π°ΡΡΠΎΡΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΡΡΠ΅Π΄ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π·Π°Π±ΡΡΡΠΈΠ½Π½ΡΠΌΠΈ Π»Π΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ°ΠΌΠΈ Π² Π½Π°ΡΠ΅ΠΌ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 24 % (10 / 41), ΡΡΠ°ΡΡΡ MSI-L ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ Π² 2,4 % (1 / 41) ΡΠ»ΡΡΠ°Π΅Π². Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ II ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ. PD-L1 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π·Π°Π±ΡΡΡΠΈΠ½Π½ΡΠΌΠΈ Π»Π΅ΠΉΠΎΠΌΠΈΠΎΡΠ°ΡΠΊΠΎΠΌΠ°ΠΌΠΈ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ ΠΊΠ°ΠΊ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ°ΡΠΊΠ΅Ρ ΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΠΌΠΈΡΠ΅Π½Ρ
Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the phenomenon of IgG4 overproduction. Literature review and own observations
Systemic vasculitis (SV) associated with anti-neutrophilic cytoplasmic antibodies is a multifactorial process characterized by the variability of the epitope specificity of anti-neutrophilic cytoplasmic antibodies and the diversity of clinical phenotypes of the disease. In recent years, there has been an increasing interest in the combination of AAV and the phenomenon of IgG4 hyperproduction, which varies widely within AAV, from anti-neutrophilic cytoplasmic antibodies products of IgG4 subclass of undetermined significance, the presence of IgG4 positive plasma cells in the foci of immunoinflammatory lesions in patients with a definite diagnosis of AAV, to the typical clinical manifestations of an IgG4-related disease (IgG4-RD). We introduce own clinical case and analyze the combined data of the literature, which included 35 cases of a combination of AAV and IgG4-related pathology, indicating existing differences in the clinical manifestations of classical IgG4-RD and when combined with AAV. The currently accumulated data allows us to discuss the allocation of a specific clinical and immunological variant of AAV with IgG4 hyperproduction, characterized by a combination of clinical manifestations of AAV and clinical and / or histological signs of IgG4-related pathology. It is important to emphasize that the allocation of phenotypes of AAV in the future may be important for the personalized choice of treatment tactics for patients
A case of isolated IgG4-related lung disease in a teenager
IgG4-related disease (IgG4-RD) is a rare immune-mediated fibroinflammatory disease that is characterized by the occurrence of nodules in one or more organs and proceeds in most patients with the elevated levels of IgG4 in serum and/or in the tissues of the affected organs. The majority of patients are elderly men, and the disease in most cases has a slowly progressing systemic course. The cases of isolated IgG4-related injury to the viscera, which are much less common than the systemic type of the disease, are a very difficult differential diagnosis, and biopsy of these organs is associated with technical difficulties and poses a threat to the patient's health. The paper describes just such a case. It is interesting from several points of view: firstly, a rare site (solitary pulmonary nodular lesion); secondly, clinical and laboratory features (childhood onset, no immunological abnormalities β both higher serum IgG4 levels and lower complement components).Clinicians should remember that IgG4-RD does not always have a systemic course and characteristic serological markers. In these cases, histological verification of the diagnosis is of particular importance. If the histological pattern of a fibroinflammatory pseudotumor is identified, especially in the presence of multiple nodules, IgG4-RD should always be included in the differential diagnosis